WilmerHale Counsels Constellation Pharmaceuticals in $60M IPO

• 7.25.2018

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, announced on July 18, 2018, the pricing of its initial public offering of 4,000,000 shares of common stock at a public offering price of $15.00 per share, for gross proceeds of $60 million.

The WilmerHale team representing Constellation is led by Lia Der Marderosian and includes Steven Singer, Craig Hilts, Caroline Dotolo, Hilary Baker-Jennings, Kimberly Wethly and Meghan Walsh.

Read Constellation’s press release about the IPO.